HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical formulation development of Plasmodium falciparum malaria vaccine candidates based on Pfs48/45, Pfs230, and PfCSP.

Abstract
Two malaria transmission-blocking vaccine (TBV) candidates, R0.6C and ProC6C, have completed preclinical development including the selection of adjuvants, Alhydrogel® with or without the saponin based adjuvant Matrix-M™. Here, we report on the final drug product (formulation) design of R0.6C and ProC6C and evaluate their safety and biochemical stability in preparation for preclinical and clinical pharmacy handling. The point-of-injection stability studies demonstrated that both the R0.6C and ProC6C antigens are stable on Alhydrogel in the presence or absence of Matrix-M for up to 24 h at room temperature. As this is the first study to combine Alhydrogel and Matrix-M for clinical use, we also evaluated their potential interactions. Matrix-M adsorbs to Alhydrogel, while not displacing the > 95 % adsorbed protein. The R0.6C and ProC6C formulations were found to be safe and well tolerated in repeated dose toxicity studies in rabbits generating high levels of functional antibodies that blocked infection of mosquitoes. Further, the R0.6C and ProC6C drug products were found to be stable for minimally 24 months when stored at 2-8 °C, with studies ongoing through 36 months. Together, this data demonstrates the safety and suitability of the L. lactis expression system as well as supports the clinical testing of the R0.6C and ProC6C malaria vaccine candidates in First-In-Human clinical trials.
AuthorsJordan Plieskatt, Peter Bang, Grith Krøyer Wood, Mohammad Naghizadeh, Susheel K Singh, Matthijs M Jore, Michael Theisen
JournalVaccine (Vaccine) Vol. 42 Issue 8 Pg. 1980-1992 (Mar 19 2024) ISSN: 1873-2518 [Electronic] Netherlands
PMID38388238 (Publication Type: Journal Article)
CopyrightCopyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Chemical References
  • Aluminum Hydroxide
  • Antibodies, Protozoan
  • Antigens, Protozoan
  • Malaria Vaccines
  • Protozoan Proteins
Topics
  • Animals
  • Rabbits
  • Aluminum Hydroxide
  • Antibodies, Protozoan
  • Antigens, Protozoan
  • Malaria Vaccines (adverse effects)
  • Malaria, Falciparum (prevention & control)
  • Plasmodium falciparum
  • Protozoan Proteins

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: